| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T267 |
0-216 |
Sentence |
denotes |
Numerous MERS-CoV RBD-based subunit vaccines have been developed and extensively evaluated in available animal models since the emergence of MERS-CoV (Table 2) (Du et al., 2013c; Tai et al., 2017; Zhou et al., 2018). |
| T268 |
217-460 |
Sentence |
denotes |
In general, these subunit vaccines have strong immunogenicity and are capable of inducing high neutralizing antibodies and/or protection against MERS-CoV infection (Ma et al., 2014b; Zhang et al., 2016; Tai et al., 2017; Wang Y. et al., 2017). |
| T269 |
461-588 |
Sentence |
denotes |
Most subunit vaccines based on the MERS-CoV RBD have been described in detail in a previous review article (Zhou et al., 2019). |
| T270 |
589-772 |
Sentence |
denotes |
In this section, we will briefly introduce these RBD-targeting MERS vaccines, and compare their functionality, antigenicity, immunogenicity, and protection against MERS-CoV infection. |
